{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:30:34Z","timestamp":1793334634568,"version":"4.5.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T00:00:00Z","timestamp":1608768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antisense oligonucleotides (ASOs) have emerged as a new class of drugs to treat a wide range of diseases, including neurological indications. Spinraza, an ASO that modulates splicing of SMN2 RNA, has shown profound disease modifying effects in Spinal Muscular Atrophy (SMA) patients, energizing efforts to develop ASOs for other neurological diseases. While SMA specifically affects spinal motor neurons, other neurological diseases affect different central nervous system (CNS) regions, neuronal and non-neuronal cells. Therefore, it is important to characterize ASO distribution and activity in all major CNS structures and cell types to have a better understanding of which neurological diseases are amenable to ASO therapy. Here we present for the first time the atlas of ASO distribution and activity in the CNS of mice, rats, and non-human primates (NHP), species commonly used in preclinical therapeutic development. Following central administration of an ASO to rodents, we observe widespread distribution and target RNA reduction throughout the CNS in neurons, oligodendrocytes, astrocytes and microglia. This is also the case in NHP, despite a larger CNS volume and more complex neuroarchitecture. Our results demonstrate that ASO drugs are well suited for treating a wide range of neurological diseases for which no effective treatments are available.<\/jats:p>","DOI":"10.1093\/nar\/gkaa1235","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T15:13:33Z","timestamp":1608650013000},"page":"657-673","source":"Crossref","is-referenced-by-count":141,"title":["The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration"],"prefix":"10.1093","volume":"49","author":[{"given":"Paymaan","family":"Jafar-nejad","sequence":"first","affiliation":[{"name":"Ionis Pharmaceuticals Inc. Carlsbad, CA\u00a092010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Powers","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc. Carlsbad, CA\u00a092010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Soriano","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc. Carlsbad, CA\u00a092010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien","family":"Zhao","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc. Carlsbad, CA\u00a092010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A","family":"Norris","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc. Carlsbad, CA\u00a092010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Matson","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc. Carlsbad, CA\u00a092010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"DeBrosse-Serra","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc. Carlsbad, CA\u00a092010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Watson","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc. Carlsbad, CA\u00a092010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmakumar","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc. Carlsbad, CA\u00a092010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung\u00a0J","family":"Chun","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc. Carlsbad, CA\u00a092010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curt","family":"Mazur","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc. Carlsbad, CA\u00a092010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Kordasiewicz","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc. Carlsbad, CA\u00a092010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric E","family":"Swayze","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc. Carlsbad, CA\u00a092010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-3309","authenticated-orcid":false,"given":"Frank","family":"Rigo","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc. Carlsbad, CA\u00a092010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,24]]},"reference":[{"key":"2021012319510213300_B1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.cmet.2019.01.001","article-title":"RNA-targeted therapeutics","volume":"29","author":"Crooke","year":"2019","journal-title":"Cell Metab."},{"key":"2021012319510213300_B2","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs","volume":"279","author":"Wu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2021012319510213300_B3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2021012319510213300_B4","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/363260a0","article-title":"Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions","volume":"363","author":"Wahlestedt","year":"1993","journal-title":"Nature"},{"key":"2021012319510213300_B5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0306-4522(93)90426-G","article-title":"Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA","volume":"55","author":"Weiss","year":"1993","journal-title":"Neuroscience"},{"key":"2021012319510213300_B6","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1073\/pnas.90.10.4665","article-title":"Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system","volume":"90","author":"Whitesell","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021012319510213300_B7","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"Smith","year":"2006","journal-title":"J. Clin. Invest."},{"key":"2021012319510213300_B8","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"2021012319510213300_B9","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev."},{"key":"2021012319510213300_B10","doi-asserted-by":"crossref","first-page":"eaag0481","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"2021012319510213300_B11","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","article-title":"LRRK2 antisense oligonucleotides ameliorate alpha-Synuclein inclusion formation in a Parkinson's disease mouse model","volume":"8","author":"Zhao","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2021012319510213300_B12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.neuron.2016.04.006","article-title":"Gain of toxicity from ALS\/FTD-Linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs","volume":"90","author":"Jiang","year":"2016","journal-title":"Neuron"},{"key":"2021012319510213300_B13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ana.25118","article-title":"Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease","volume":"83","author":"Hagemann","year":"2018","journal-title":"Ann. Neurol."},{"key":"2021012319510213300_B14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41586-020-2494-3","article-title":"Suppression of proteolipid protein rescues Pelizaeus-Merzbacher disease","volume":"585","author":"Elitt","year":"2020","journal-title":"Nature"},{"key":"2021012319510213300_B15","doi-asserted-by":"crossref","first-page":"e131175","DOI":"10.1172\/jci.insight.131175","article-title":"Antisense oligonucleotides extend survival of prion-infected mice","volume":"5","author":"Raymond","year":"2019","journal-title":"JCI Insight"},{"key":"2021012319510213300_B16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature22038","article-title":"Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice","volume":"544","author":"Becker","year":"2017","journal-title":"Nature"},{"key":"2021012319510213300_B17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/ana.25264","article-title":"Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice","volume":"84","author":"McLoughlin","year":"2018","journal-title":"Ann. Neurol."},{"key":"2021012319510213300_B18","doi-asserted-by":"crossref","first-page":"eaap8677","DOI":"10.1126\/scitranslmed.aap8677","article-title":"Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7","volume":"10","author":"Niu","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"2021012319510213300_B19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1\u20132 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2021012319510213300_B20","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington's disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2021012319510213300_B21","doi-asserted-by":"crossref","first-page":"e129240","DOI":"10.1172\/jci.insight.129240","article-title":"Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging","volume":"4","author":"Mazur","year":"2019","journal-title":"JCI Insight"},{"key":"2021012319510213300_B22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a central nervous system delivered 2\u2032-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021012319510213300_B23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.neuroscience.2004.11.038","article-title":"Spinal distribution and metabolism of 2\u2032-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats","volume":"131","author":"Butler","year":"2005","journal-title":"Neuroscience"},{"key":"2021012319510213300_B24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12967-020-02461-2","article-title":"Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system","volume":"18","author":"Sullivan","year":"2020","journal-title":"J. Transl. Med."},{"key":"2021012319510213300_B25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"2021012319510213300_B26","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1172\/JCI124120","article-title":"Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment","volume":"129","author":"Ramos","year":"2019","journal-title":"J. Clin. Invest."},{"key":"2021012319510213300_B27","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in Infantile-Onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2021012319510213300_B28","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2017","journal-title":"Lancet"},{"key":"2021012319510213300_B29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jneumeth.2017.02.001","article-title":"Development of a simple, rapid, and robust intrathecal catheterization method in the rat","volume":"280","author":"Mazur","year":"2017","journal-title":"J. Neurosci. Methods"},{"key":"2021012319510213300_B30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/abio.2002.5576","article-title":"Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma","volume":"304","author":"Yu","year":"2002","journal-title":"Anal. Biochem."},{"key":"2021012319510213300_B31","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/dmd.106.012401","article-title":"Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100","volume":"35","author":"Yu","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"2021012319510213300_B32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/nat.2013.0443","article-title":"Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals","volume":"23","author":"Hung","year":"2013","journal-title":"Nucleic Acid Ther."},{"key":"2021012319510213300_B33","volume-title":"Spinal Drug Delivery","author":"Yaksh","year":"1999"},{"key":"2021012319510213300_B34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1148\/radiology.157.2.4048444","article-title":"MR cisternography and myelography with Gd-DTPA in monkeys","volume":"157","author":"Di\u00a0Chiro","year":"1985","journal-title":"Radiology"},{"key":"2021012319510213300_B35","doi-asserted-by":"crossref","DOI":"10.1101\/2020.09.09.289900","article-title":"Antisense oligonucleotide therapy for SCN2A gain-of-function epilepsy","author":"Li","year":"2020"},{"key":"2021012319510213300_B36","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI99081","article-title":"Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models","volume":"128","author":"McCampbell","year":"2018","journal-title":"J. Clin. Invest."},{"key":"2021012319510213300_B37","doi-asserted-by":"crossref","first-page":"eaar3959","DOI":"10.1126\/scitranslmed.aar3959","article-title":"Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease","volume":"10","author":"Southwell","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"2021012319510213300_B38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.neuron.2005.12.001","article-title":"Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease","volume":"48","author":"Monani","year":"2005","journal-title":"Neuron"},{"key":"2021012319510213300_B39","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35097565","article-title":"From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS","volume":"2","author":"Cleveland","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"2021012319510213300_B40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fnana.2014.00152","article-title":"Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update","volume":"8","author":"Brichta","year":"2014","journal-title":"Front. Neuroanat"},{"key":"2021012319510213300_B41","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: an update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"2021012319510213300_B42","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41582-018-0051-6","article-title":"Spinocerebellar ataxias: prospects and challenges for therapy development","volume":"14","author":"Ashizawa","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"2021012319510213300_B43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature16159","article-title":"Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides","volume":"528","author":"Sztainberg","year":"2015","journal-title":"Nature"},{"key":"2021012319510213300_B44","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1021\/acs.jmedchem.5b01948","article-title":"Comprehensive structure-activity relationship of triantennary N-Acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes","volume":"59","author":"Prakash","year":"2016","journal-title":"J. Med. Chem."},{"key":"2021012319510213300_B45","doi-asserted-by":"crossref","first-page":"eaat3386","DOI":"10.1126\/sciadv.aat3386","article-title":"Targeted delivery of antisense oligonucleotides to pancreatic beta-cells","volume":"4","author":"Ammala","year":"2018","journal-title":"Sci. Adv."},{"key":"2021012319510213300_B46","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1172\/JCI125228","article-title":"Selective tissue targeting of synthetic nucleic acid drugs","volume":"129","author":"Seth","year":"2019","journal-title":"J. Clin. Invest."},{"key":"2021012319510213300_B47","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/B978-0-444-64076-5.00044-2","article-title":"Alexander disease","volume":"148","author":"Messing","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"2021012319510213300_B48","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.neuropharm.2016.04.026","article-title":"Contribution of the oligodendrocyte lineage to CNS repair and neurodegenerative pathologies","volume":"110","author":"Tognatta","year":"2016","journal-title":"Neuropharmacology"},{"key":"2021012319510213300_B49","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"2021012319510213300_B50","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"2021012319510213300_B51","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1080\/19420862.2017.1345834","article-title":"Pharmacokinetics of an intracerebroventricularly administered antibody in rats","volume":"9","author":"Noguchi","year":"2017","journal-title":"MAbs"},{"key":"2021012319510213300_B52","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2165\/00003088-200140120-00003","article-title":"Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations","volume":"40","author":"Thorne","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"2021012319510213300_B53","doi-asserted-by":"crossref","first-page":"134310","DOI":"10.1016\/j.neulet.2019.134310","article-title":"Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges","volume":"707","author":"Maes","year":"2019","journal-title":"Neurosci. Lett."}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/nar\/article-pdf\/49\/2\/657\/36085025\/gkaa1235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/nar\/article-pdf\/49\/2\/657\/36085025\/gkaa1235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,18]],"date-time":"2021-04-18T00:03:41Z","timestamp":1618704221000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article\/49\/2\/657\/6047287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,24]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,12,24]]},"published-print":{"date-parts":[[2021,1,25]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gkaa1235","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.31.216721","asserted-by":"object"}]},"ISSN":["0305-1048","1362-4962"],"issn-type":[{"value":"0305-1048","type":"print"},{"value":"1362-4962","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,25]]},"published":{"date-parts":[[2020,12,24]]}}}